Seat­tle’s Im­pel Neu­roPhar­ma bags $67.5M crossover raise for a round of new drug/de­vice CNS clin­i­cal tri­als

A Seat­tle-based drug/de­vice com­pa­ny with its own par­tic­u­lar ap­proach for get­ting drugs de­liv­ered in­to the brain through the nose has put to­geth­er a top-notch syn­di­cate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER